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summaries
combination chemotherapY
A phase II study of gemcitabine combined 
with vinorelbine as first-line chemotherapy for 
metastatic breast cancer
Of 72 evaluable patients with locally advanced or metastatic breast 
cancer, Meshref and colleagues report that 4 patients (6%) had a 
complete response and 26 patients (36%) had a partial response to 
combination gemcitabine/vinorelbine therapy. Nineteen patients 
(26%) had stable disease and 17 patients (24%) had progressive 
disease, with a median time to disease progression of 37 weeks. 
The toxic effects were manageable and consisted mainly of grade 
3-4 febrile neutropenia, nausea, diarrhea and stomatitis. The 
combination showed promising efficacy and good tolerability.
A meta-analysis of highly active anti-retroviral 
therapy for treatment of plasmablastic lymphoma
A meta-analysis by Guan and colleagues showed that the progno-
sis for plasmblastic lymphoma was improved in patients receiving 
HAART in addition to chemotherapy and/or radiotherapy than 
in patients receiving chemotherapy and/or radiotherapy alone, 
but the small sample sizes in the eight individual studies raise the 
likelihood of bias. The results should be taken cautiously. Larger 
studies are needed to determine whether addition of HAART 
carries a survival advantage.
A phase II study of high-dose celecoxib and 
metronomic ‘low-dose’ cyclophosphamide and 
methotrexate in patients with relapsed and 
refractory lymphoma
In 41 patients with relapsed and/or refractory diffuse large B-cell 
lymphoma who were not candidates for bone marrow transplan-
tation, El Bary and colleagues report a reasonable outcome and 
acceptable toxicity with metronomic chemotherapy and a COX-2 
inhibitor, which has been shown to reduce the incidence of neo-
plastic lesions in preclinical studies. They recommend that met-
ronomic chemotherapy be considered after standard approaches 
have been explored.
immunotherapY
Gibbon-ape-leukemia virus transduction of 
peripheral blood CD34+ derived dendritic cells
Alimoghaddam and colleagues explored the possibility of creat-
ing genetically modified dendritic cells for immunotherapy by 
assessing the efficacy of GALV transduction of CD34+ derived 
dendritic cells. The majority of CD34+ cells were successfully 
transduced into cells identical to dendritic cells according to mor-
phology and immunophenotyping features.
cancer bioloGY
Identification of a novel peptide derived from the 
M-phase phosphoprotein 11 (MMP11) leukemic 
antigen recognized by human CD8 cytotoxic T 
lymphocytes
Al Qudaihi and colleagues identified a potential HLA binding 
epitope derived from the MPP11 protein, which was used to gen-
erate a CD8+ cytotoxic T lymphocyte line that had toxic effects 
on a CML cell line. The MPP11 antigen, which is overexpressed 
in leukemic cells, may be an attractive target for leukemia T cell 
therapy.
